Increased serum prolidase activity was well documented in certain cancers like pancreatic cancer, lung carcinoma, breast cancer, Stage 1 endometrial cancer, stomach cancer, ovarian cancer [38–40], and so forth. This evidence concerns the gene PEPD and gastric cancer.